Mesenchymal Stem Cell Transplantation for Liver Cell Failure: A New Direction and Option
Background and Aims. Mesenchymal stem cell transplantation (MSCT) became available with liver failure (LF), while the advantages of MSCs remain controversial. We aimed to assess clinical advantages of MSCT in patients with LF. Methods. Clinical researches reporting MSCT in LF patients were searched...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2018/9231710 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832564712393408512 |
|---|---|
| author | Yantian Cao Bangjie Zhang Rong Lin Qingzhi Wang Jie Wang Fangfang Shen |
| author_facet | Yantian Cao Bangjie Zhang Rong Lin Qingzhi Wang Jie Wang Fangfang Shen |
| author_sort | Yantian Cao |
| collection | DOAJ |
| description | Background and Aims. Mesenchymal stem cell transplantation (MSCT) became available with liver failure (LF), while the advantages of MSCs remain controversial. We aimed to assess clinical advantages of MSCT in patients with LF. Methods. Clinical researches reporting MSCT in LF patients were searched and included. Results. Nine articles (n=476) related with LF patients were enrolled. After MSCT, alanine aminotransferase (ALT) baseline decreased largely at half a month (P<0.05); total bilirubin (TBIL) baseline declined to a certain stable level of 78.57 μmol/L at 2 and 3 months (P<0.05). Notably, the decreased value (D value) of Model for End-Stage Liver Disease score (MELD) of acute-on-chronic liver failure (ACLF) group was higher than that of chronic liver failure (CLF) group (14.93 ± 1.24 versus 4.6 ± 5.66, P<0.05). Moreover, MELD baseline of ≥20 group was a higher D value of MELD than MELD baseline of <20 group with a significant statistical difference after MSCT (P=0.003). Conclusion. The early assessment of the efficacy of MSCT could be based on variations of ALT at half a month and TBIL at 2 and 3 months. And it had beneficial effects for patients with LF, especially in ACLF based on the D value of MELD. |
| format | Article |
| id | doaj-art-d2887d90f464472abe43963f3024aeea |
| institution | Kabale University |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-d2887d90f464472abe43963f3024aeea2025-02-03T01:10:26ZengWileyGastroenterology Research and Practice1687-61211687-630X2018-01-01201810.1155/2018/92317109231710Mesenchymal Stem Cell Transplantation for Liver Cell Failure: A New Direction and OptionYantian Cao0Bangjie Zhang1Rong Lin2Qingzhi Wang3Jie Wang4Fangfang Shen5Department of Gastroenterology, The Third Affiliated Hospital, Xinxiang Medical University, Hua Lan Avenue, Xinxiang, Henan Province 453003, ChinaDepartment of Gastroenterology, The Third Affiliated Hospital, Xinxiang Medical University, Hua Lan Avenue, Xinxiang, Henan Province 453003, ChinaDepartment of Gastroenterology, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, Hubei Province 430022, ChinaDepartment of Gastroenterology, The Third Affiliated Hospital, Xinxiang Medical University, Hua Lan Avenue, Xinxiang, Henan Province 453003, ChinaM. M. School of Automation, Key Laboratory of Image Processing and Intelligent Control of Education Ministry of China, Huazhong University of Science and Technology, Wuhan, Hubei Province 430022, ChinaThe Key Laboratory for Tumor Translational Medicine, The Third Affiliated Hospital, Xinxiang Medical University, Hua Lan Avenue, Xinxiang, Henan Province 453003, ChinaBackground and Aims. Mesenchymal stem cell transplantation (MSCT) became available with liver failure (LF), while the advantages of MSCs remain controversial. We aimed to assess clinical advantages of MSCT in patients with LF. Methods. Clinical researches reporting MSCT in LF patients were searched and included. Results. Nine articles (n=476) related with LF patients were enrolled. After MSCT, alanine aminotransferase (ALT) baseline decreased largely at half a month (P<0.05); total bilirubin (TBIL) baseline declined to a certain stable level of 78.57 μmol/L at 2 and 3 months (P<0.05). Notably, the decreased value (D value) of Model for End-Stage Liver Disease score (MELD) of acute-on-chronic liver failure (ACLF) group was higher than that of chronic liver failure (CLF) group (14.93 ± 1.24 versus 4.6 ± 5.66, P<0.05). Moreover, MELD baseline of ≥20 group was a higher D value of MELD than MELD baseline of <20 group with a significant statistical difference after MSCT (P=0.003). Conclusion. The early assessment of the efficacy of MSCT could be based on variations of ALT at half a month and TBIL at 2 and 3 months. And it had beneficial effects for patients with LF, especially in ACLF based on the D value of MELD.http://dx.doi.org/10.1155/2018/9231710 |
| spellingShingle | Yantian Cao Bangjie Zhang Rong Lin Qingzhi Wang Jie Wang Fangfang Shen Mesenchymal Stem Cell Transplantation for Liver Cell Failure: A New Direction and Option Gastroenterology Research and Practice |
| title | Mesenchymal Stem Cell Transplantation for Liver Cell Failure: A New Direction and Option |
| title_full | Mesenchymal Stem Cell Transplantation for Liver Cell Failure: A New Direction and Option |
| title_fullStr | Mesenchymal Stem Cell Transplantation for Liver Cell Failure: A New Direction and Option |
| title_full_unstemmed | Mesenchymal Stem Cell Transplantation for Liver Cell Failure: A New Direction and Option |
| title_short | Mesenchymal Stem Cell Transplantation for Liver Cell Failure: A New Direction and Option |
| title_sort | mesenchymal stem cell transplantation for liver cell failure a new direction and option |
| url | http://dx.doi.org/10.1155/2018/9231710 |
| work_keys_str_mv | AT yantiancao mesenchymalstemcelltransplantationforlivercellfailureanewdirectionandoption AT bangjiezhang mesenchymalstemcelltransplantationforlivercellfailureanewdirectionandoption AT ronglin mesenchymalstemcelltransplantationforlivercellfailureanewdirectionandoption AT qingzhiwang mesenchymalstemcelltransplantationforlivercellfailureanewdirectionandoption AT jiewang mesenchymalstemcelltransplantationforlivercellfailureanewdirectionandoption AT fangfangshen mesenchymalstemcelltransplantationforlivercellfailureanewdirectionandoption |